Duhaney Clinical Trials Investment Dashboard
SKU: 88867085907

Duhaney Clinical Trials Investment Dashboard

Sale price$5400.00 Regular price$6000.00
Save 10%

Shipping Estimate
USA
  • USA
  • CAN

Ships within 48 hours · Estimated delivery Jul 8 - Jul 13

Promo Codes Available:

For Your Every Summer RSVP, with Code: SUMMER15

Description

Duhaney Clinical Trials Investment DashboardDuhaney Real Estate Deal Command Center Full Ecosystem Duhaney Clinical Trials Investment Dashboard Your Insider Guide to Drug Success & ROI Starting Price: $1500. 00 USD The Truth About Clinical Trials Nobody Tells You If youve ever tried to predict which drug will win FDA approval, or which trial will attract the next big investment, you already know the truth **the data is scattered, outdated, and full of noise**. Most clinical reports tell you

Duhaney Real Estate Deal Command Center – Full Ecosystem

Duhaney Clinical Trials Investment Dashboard – Your Insider Guide to Drug Success & ROI

Starting Price: $1500.00 USD

The Truth About Clinical Trials Nobody Tells You

If you’ve ever tried to predict which drug will win FDA approval, or which trial will attract the next big investment, you already know the truth — **the data is scattered, outdated, and full of noise**.

Most clinical reports tell you **what happened**, but they never tell you **what it really means for your investment, your startup, or your next move**.

---

Let’s Deframe That Entire Process

Why guess when you could have a **real-time dashboard** that connects the dots between:

  • ✅ Which sponsors dominate in each therapeutic area
  • ✅ The **real cost per patient** by condition and phase
  • ✅ The historical **ROI for every major trial category**
  • ✅ Which drugs have **the highest probability of approval**
  • ✅ And exactly which conditions are pulling the most investment dollars right now

---

Now Let’s Reframe — What You’re Actually Getting

The **Duhaney Clinical Trials Investment Dashboard** isn’t a static report — it’s your **decision engine**. Every time you need to answer questions like:

  • 💰 Which drug is about to make investors rich?
  • 📊 Which sponsor should my startup partner with?
  • ⚕️ Which condition is about to have a blockbuster approval?
  • 📈 What’s the **per-patient cost vs revenue potential** for each drug?
  • 🔍 Which trials are actually worth tracking — and which are just noise?

…you load the dashboard and the answers are right there.

---

What’s Inside Your Personalized Dashboard

✅ Pre-loaded with the **top 50 therapeutic areas** (Sickle Cell, Oncology, Rare Diseases, and more) ✅ Full **financial modeling** — cost per patient, projected revenue per patient, and calculated ROI ✅ FDA study phases & statuses — see which trials are closest to approval ✅ Sponsor and CRO performance tracking — know who delivers and who burns money ✅ Real-time NCT Number cross-referencing — no more disconnected data

---

Why This Dashboard is Different

✅ **Built directly from FDA clinicaltrials.gov data** — no second-hand garbage ✅ **Includes historical AND current data** — so you can track trends, not just snapshots ✅ **Custom-built to your needs** — you tell us your focus (condition, phase, region, sponsor type) and we personalize the dashboard to fit you.

---

Call Before Purchase – Here’s Why

Because this isn’t a one-size-fits-all product. Every investor, startup, or pharma exec has a unique focus — oncology vs rare disease, early-stage vs late-stage trials, US vs global markets.

That’s why you must call me directly before purchase, so I can personally customize your dashboard to fit your strategy.

Contact Rohan Duhaney
Phone: (856) 522-3601
Email: [email protected]

---

Future Price Increases

The current price of **$1500.00 USD** reflects the early release version. As new data sources, advanced modeling, and predictive AI get added, the price will increase significantly.

**Secure your personalized dashboard now at today’s rate — and lock in free updates for the first 60 days.**

---

Ready to See What Real Clinical Intelligence Feels Like?

Call me today — and let’s build your **custom intelligence engine** so you can make smarter, faster decisions in clinical development and biotech investing.

Rohan Duhaney

Phone: 856-522-3601
Email: [email protected]
Website: smartduhaney.com

 

PROOF OF WORK

 


        Healthcare Solutions Dashboard Output
        Brought to you by Rohan Duhaney
        Contact: 856-522-3601 | Email: [email protected] | Website: smartduhaney.com
        ----------------------------------------------------------------------
        Condition: Sickle Cell Disease
        Cure: DRUG: ATG|DRUG: fludarabine|DRUG: cyclophosphamide|RADIATION: Total body irradiation|PROCEDURE: Stem cell infusion|DRUG: Sirolimus|DRUG: mycophenolate mofetil

        For Investors only investing in a study:
        Financial Forecast:
        • Total Cost per Patient: $250,000.00
        • Total Revenue per Patient: $2,100,000.00
        • ROI: 740.0%

        NCT Number: NCT03121001
        Study Phase: PHASE2
        Study Status: RECRUITING

        Additional Insights:
        • Devices/Interventions: No device listed
        • Enrollment: 50
        • Sponsor: University of Illinois at Chicago
        ----------------------------------------------------------------------
        

        Healthcare Solutions Dashboard Output
        Brought to you by Rohan Duhaney
        Contact: 856-522-3601 | Email: [email protected] | Website: smartduhaney.com
        ----------------------------------------------------------------------
        Condition: HbS Disease|Hemoglobin S Disease|Sickle Cell Anemia|Sickle Cell Disorders|Sickling Disorder Due to Hemoglobin S|Sickle Cell Disease
        Cure: OTHER: TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation|OTHER: Matched sibling donor transplantation

        For Investors only investing in a study:
        Financial Forecast:
        • Total Cost per Patient: $1,060,000.00
        • Total Revenue per Patient: $8,904,000.00
        • ROI: 740.0%

        NCT Number: NCT04201210
        Study Phase: PHASE2
        Study Status: RECRUITING

        Additional Insights:
        • Devices/Interventions: No device listed
        • Enrollment: 212
        • Sponsor: University of Regensburg
        ----------------------------------------------------------------------
        

        Healthcare Solutions Dashboard Output
        Brought to you by Rohan Duhaney
        Contact: 856-522-3601 | Email: [email protected] | Website: smartduhaney.com
        ----------------------------------------------------------------------
        Condition: Sickle Cell Disease|Diffuse Myocardial Fibrosis
        Cure: DRUG: Losartan

        For Investors only investing in a study:
        Financial Forecast:
        • Total Cost per Patient: $120,000.00
        • Total Revenue per Patient: $1,008,000.00
        • ROI: 740.0%

        NCT Number: NCT05012631
        Study Phase: PHASE2
        Study Status: RECRUITING

        Additional Insights:
        • Devices/Interventions: No device listed
        • Enrollment: 24
        • Sponsor: Children's Hospital Medical Center, Cincinnati
        ----------------------------------------------------------------------
        We HAVE UNLIMITED INFORMATION READY TO EXPLORE

Shipping Notes
  • Free Standard Shipping on $100+ Orders to the USA.
  • Except Preorder products are shipped in 48 hours.
  • Delivery to the USA:
  1. Standard Shipping : 3-10 business days
  • If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy
SKU: 88867085907

Discover Niche Categories That Outsell

Top-Converting Item to Boost Your Average Order

4.1 ★★★★★
Based on 1081 reviews
Sort
Highest Rating
Newest First
Oldest First
Product Reviews
A
Verified Purchase
Amazon Customer
Lowell, US
★★★★★ 5
Loved this cleanser
I really love this cleanser. I use it every night to take off my sunscreen and my skin looks great. I enjoy that it doesn’t dry out the skin and it’s great for mascara. It’s very gentle as well and doesn’t sting your eyes. Will be buying again once I’m done.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 10, 2026
K
Verified Purchase
Karrington
Lowell, US
★★★★★ 5
Product review from a teenage girl
Has helped my fungal acne very well and has calmed down my breakouts I get monthly. There’s no scent and it feels very soft in the skin. Easy to rinse off and easy to use. Helps out my dry skin and makes me feel smooth after using.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 28, 2026
M
Verified Purchase
MW
San Leandro, US
★★★★★ 5
Gentle and non-greasy cleanser.
Gentle on mature skin. No fragrance. Non-greasy. This is my double cleanser to remove makeup and this first step gets my face make up free and feels very clean.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 22, 2026
M
Verified Purchase
Michele Riggs
Lowell, US
★★★★★ 5
Game changer
I use this cleanser with the other cleanser they have, the green one. It’s actually crazy how much it changed my skin routine. I didn’t change my products and only my cleansers and there was a huge improvement. Using them both together feels very nice, there is literally a slight glow on my face after i’m done washing it. The cleanser itself is an oil and helps get my makeup off well. My face is usually oily but my t-zone can be a bit dry, these combined helped my face go back to a “normal” balance. So happy with my purchase, definitely recommend.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 25, 2026
M
Verified Purchase
M. Dalbey
Dallas, US
★★★★★ 4
Removes Makeup Well
Removes makeup well, and doesn't leave the skin too oily. Didn't cause me breakouts. Just clean skin. However, if you have sensitive eyes and skin, avoid the eye area. I had burning and discomfort around the eyes
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 16, 2026

recommand products